Sangamo Biosciences, Inc. (NASDAQ: SGMO) reported Q2 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $7.84 million.

For earnings history and earnings-related data on Sangamo Biosciences, Inc. (SGMO) click here.